MOLECULAR DIAGNOSTIC KIT FOR DETECTING NUCLEOTIDE SEQUENCES AND METHODS FOR DETECTING INFECTIOUS AGENTS USING SAID KIT

Abstract

Molecular-based diagnostic kits and methods for detecting nucleotide sequences of DNA, DNA copy and RNA of infectious agents, transgenes, alleles or non-encoding sequences, with no initial isolation are provided. The kit comprises at least a first calibrated dropper bottle with an anti-contamination system containing a solution of polymerase enzyme, chaotropic agents, salts and deoxyribonucleotides; a second calibrated dropper bottle with an anti-contamination system containing a set of at least 4 primers, part of the sequences being preserved in the nucleic acid fragment to be detected; a dropper bottle containing a mixture of developing reagents; a carrier to hold the sample; at least one LFD developing system, colorimetric or fluorogenic reaction; positive and negative controls. The polymerase enzyme is selected from Bst enzymes formed by DNA polymerase/helicase, with no exonuclease activity. The set of primers is designed from gene sequences to be detected, whether of deoxyribonucleic or ribonucleic nature.

Claims

1-10. (canceled)

11. A molecular-based diagnostic kit for detecting in biological samples the presence of nucleotide sequences of Trypanosoma cruzi, an agent causing the Chagas disease, specially designed to be used at “point-of-care” (POC) diagnostic centers, said kit comprising: a first vial with an anti-contamination system that contains a solution of the polymerase enzyme, saline components, chaotropic agents and deoxyribonucleotides, wherein the polymerase enzyme is selected from the BST enzyme family, which consists of DNA polymerase/helicase, with no exonuclease activity; optionally, a second vial with an anti-contamination system that contains a set of at least 4 primers, with at least part of its sequences being preserved in the nucleic acid fragment to be detected, wherein the set of primers is selected from the genome sequences or fragment to be detected, whether of deoxyribonucleic or ribonucleic nature; a container to hold the sample to be tested, selected from a reaction tube and a reaction tray, wherein said container can hold in its interior a sample optionally on a carrier and reagents, be closed and heated so that the reaction takes place during an incubation time; once the incubation time is completed, at least a developing system by LFD dipstick (“Lateral Flow Dipsticks”) or, alternatively, by change of indicating dye; and positive and negative controls; said diagnostic kit CHARACTERIZED in that: the set of at least 4 primers comprises SAT gene sequences selected from: TABLE-US-00008 F3-ACAGAGAGTGCCTCTGA, B3- GTCAATATCTGTTTGCG, FIP-CACTCGGCTGATCGTTTTCGACCCCCATCATTCATAATTGGA, BIP-GGCAAGAGCTCGCGAAATTCCACACACTGGACACCAAA, Lb-TCCAAGCAGCGGATAATTCA, and Lf-TGCATCACATGTTGTGGTCTA; and wherein the vials are calibrated dropper bottles with an anti-contamination system.

12. The diagnostic kit of claim 11, CHARACTERIZED in that said kit comprises a single dropper bottle with an anti-contamination system that provides a complete mixture of reagents, excluding the indicating dye of the reaction which is dispensed in dehydrated state in each container to place the sample to be tested.

13. The diagnostic kit of claim 11, CHARACTERIZED in that said kit comprises a single dropper bottle with an anti-contamination system that provides a complete mixture of reagents, excluding the indicating dye of the reaction and the primers which are dispensed in dehydrated status in each container to place the sample to be tested.

14. The diagnostic kit of claim 11, CHARACTERIZED in that the reaction tray is a container that is provided with a hermetic seal and a lateral slot for introduction of dipsticks.

15. The diagnostic kit of claim 11, CHARACTERIZED in that the developing system alternatively consists of chromatography LFD dipsticks that consist of a total of two bands or lines, a top one and a bottom one; or, the developing system consists of color change, when the sample is DNA or blood in saline solution, that does not interfere with said process.

16. A method for detecting the presence of Trypanosoma cruzi, an etiological agent of Chagas disease, of a DNA sample, blood diluted in physiological solution or directly of a fragment of absorbent or Guthrie paper with a dispensed dried blood drop obtained from neonatal research cards, using the diagnostic kit of claim 11, said method comprising: placing at least one drop from the first calibrated dropper bottle that contains the buffer (saline components, chaotropic agents and deoxyribonucleotides) with the enzyme mixture and at least one drop from the second calibrated dropper bottle that contains the primers, into the reaction tube or, alternatively, placing at least one drop from the single calibrated dropper bottle that contains all the components necessary for amplification and reading, excluding one or any of the reaction components that are present in dehydrated state in the reaction tube, placing the sample to be tested into the reaction tube, which sample consists of isolated/purified DNA, blood diluted in physiological solution or directly a fragment of absorbent paper or Guthrie card with the dried blood to be tested obtained from neonatal research, with no extraction process, closing the reaction tube, mixing until homogenization of solution ingredients, incubating at 63-65° C. for 60 minutes, removing the heat source, and reading the obtained result as follows: in the case of reading by LFD: adding one drop from the calibrated dropper bottle having the developing solution into the reaction tube, introducing a LFD into the reaction tube, allowing the contents of the reaction tube to progress by capillarity along the LFD for some 1-2 minutes, removing the LFD, wherein 2 bands is a reagent positive result, 1 band is a reagent negative result, and no band is an invalid result, over a total of two bands, a top one and a bottom one on the LFD; or in the case of color change reading: observing the color of the reaction contents, and comparing the color of the reaction contents with the negative and positive controls of the reaction: in case the initial color remains and is similar to the white color of the reaction used as negative control, the obtained result is a reagent negative result; if the reaction has changed its color the same as the color of the positive control, the obtained result is a reagent positive result; if no color is seen, the obtained result is an invalid result.

17. The method of claim 16, CHARACTERIZED in that the kit is kept stable without modifying diagnostic sensitivity and specificity under cooled conditions at 2-8° C. for a period of at least 18 months.

18. The method of claim 16, CHARACTERIZED in that the sample is used with no prior extraction and/or purification.

19. A set of primers useful in the method of claim 16, CHARACTERIZED in that the set of primers comprises SAT gene sequences selected from: TABLE-US-00009 F3-ACAGAGAGTGCCTCTGA, B3- GTCAATATCTGTTTGCG, FIP-CACTCGGCTGATCGTTTTCGACCCCCATCATTCATAATTGGA, BIP-GGCAAGAGCTCGCGAAATTCCACACACTGGACACCAAA, Lb-TCCAAGCAGCGGATAATTCA, and Lf-TGCATCACATGTTGTGGTCTA.

20. A method of preparing an amplification solution useful in the method of claim 16, comprising: using primers comprising SAT gene sequences selected from: TABLE-US-00010 F3-ACAGAGAGTGCCTCTGA, B3- GTCAATATCTGTTTGCG, FIP-CACTCGGCTGATCGTTTTCGACCCCCATCATTCATAATTGGA, BIP-GGCAAGAGCTCGCGAAATTCCACACACTGGACACCAAA, Lb-TCCAAGCAGCGGATAATTCA, and Lf-TGCATCACATGTTGTGGTCTA.

21. A molecular-based diagnostic kit for detecting in biological samples the presence of SARS-CoV-2, an agent causing COVID-19, specially designed to be used at “point-of-care” (POC) diagnostic centers, said kit comprising: a first vial with an anti-contamination system, containing a solution of the polymerase enzyme, a reverse transcriptase, saline components, chaotropic agents and deoxyribonucleotides, wherein the polymerase enzyme is selected from the BST enzyme family, which consists of DNA polymerase/helicase, with no exonuclease activity, and optionally, a second vial having a set of at least 4 primers, with at least part of its sequences being preserved in the nucleic acid fragment to be detected, wherein the set of primers is selected from the genome sequences or fragment to be detected, whether of deoxyribonucleic or ribonucleic nature; a container to hold the sample to be tested, selected from a reaction tube and a reaction tray, wherein said container can hold in its interior a sample optionally on a carrier and reagents, be closed and heated so that the reaction takes place during an incubation time; once the incubation time is completed, at least a developing system by LFD dipstick (“Lateral Flow Dipsticks”) or, alternatively, by change of indicating dye; and positive and negative controls; said diagnostic kit CHARACTERIZED in that: the set of at least 4 primers comprises: R1Aa2 sequences selected from: TABLE-US-00011 F3-TGCTTGTGAAATTGTCGGT, B3-GCCAGTTTCTTCTCTGGAT, FIP-TCAGCACACAAAGCCAAAAATTTATAAATTGTCACCTGTGCAAAG, BIP-TATTGGTGGAGCTAAACTTAAAGCCACACTTTCTGTACAATCCCT T, Lb-GAATTTAGGTGAAACATTTGTCACG, and Lf- CTTAAAGAATGTCTGAACACTCTCC, and pE-2 sequences selected from: TABLE-US-00012 F3-CCGACGACGACTACTAGC, B3-GACTCACGTTAACAATATTGCA, FIP-ACTATTAACGTACCTGTCTCTTCCGGTGCCTTTGTAAGCACAAG, BIP-AGCGTACTTCTTTTTCTTGCTTTCGCAGTACGCACACAATCGA, Lb-CTTGCTAGTTACACTAGCCATCCT, and Lf- CGAATGAGTACATAAGTTCGTACTC; and wherein the vials are calibrated dropper bottles with an anti-contamination system.

22. The diagnostic kit of claim 21, CHARACTERIZED in that said kit comprises a single calibrated dropper bottle with an anti-contamination system that provides a complete mixture of reagents, excluding the enzymatic component which is dispensed in dehydrated state in each container to place the sample to be tested.

23. The diagnostic kit of claim 21, CHARACTERIZED in that said kit comprises a single calibrated dropper bottle with an anti-contamination system that provides a complete mixture of reagents, excluding the indicating dye of the reaction which is provided as dispensed in dehydrated state in each container where the sample to be tested is placed.

24. The diagnostic kit of claim 21, CHARACTERIZED in that said kit comprises a single calibrated dropper bottle with an anti-contamination system that provides a complete mixture of reagents, excluding the indicating dye of the reaction and the primers which are dispensed in dehydrated state in each container where the sample to be tested is placed.

25. The diagnostic kit of claim 21, CHARACTERIZED in that the developing system alternatively consists of chromatography LFD dipsticks that comprise a total of two bands or lines, a top one and a bottom one; or the developing system consists of color change.

26. A method for detecting the presence of SARS-CoV-2, an agent of COVID-19, in biological samples, using the diagnostic kit of claim 21, said comprising: placing at least one drop from the first calibrated dropper bottle that contains the buffer (saline components, chaotropic agents and deoxyribonucleotides) with the mixture of enzymes and at least one drop from the second calibrated dropper bottle that contains the primers, into the reaction tube or, alternatively, placing at least one drop from the single calibrated dropper bottle that contains all components necessary for amplification and reading excluding one or any of the reaction components that are present in dehydrated state in the reaction tube, placing the sample to be tested into the reaction tube, which sample consists of isolated DNA or directly a sample of nasopharyngeal or buccopharingeal swab or saliva, placed in the lysis buffer or inactivated by heat, with no extraction process, closing the reaction tube, mixing until homogenization of solution ingredients, incubating at 63-65° C. for 60-90 minutes, removing the heat source, and reading the obtained result as follows: in the case of reading by LFD: adding into the reaction tube one drop from the calibrated dropper bottle that has the developing solution, introducing a LFD into the reaction tube, allowing the contents of the reaction tube to progress by capillarity along the LFD for some 1-2 minutes, removing the LFD, and reading the result, wherein 2 bands is a reagent positive result, 1 band is a reagent negative result, and no band is an invalid result, over a total of two bands, a top one and a bottom one on the LFD; or in the case of color change reading: observing the color of the reaction contents, and comparing the color of the reaction contents with the negative and positive controls of the reaction: in case the initial color remains and is similar to the white color of the reaction used as negative control, the obtained result is a reagent negative result; or if the reaction has changed its color the same as the color of the positive control, the obtained result is a reagent positive result; if no color is seen, the obtained result is an invalid result.

27. The method of claim 26, CHARACTERIZED in that the kit is kept stable without modifying diagnostic sensitivity and specificity under cooled conditions at 2-8° C. for periods of at least 18 months.

28. The method of claim 26, CHARACTERIZED in that the sample is used with no prior extraction and/or purification.

29. A set of primers for use in the method of claim 26, CHARACTERIZED in that the primers comprise: R1Aa2 sequences selected from: TABLE-US-00013 F3-TGCTTGTGAAATTGTCGGT, B3-GCCAGTTTCTTCTCTGGAT, FIP-TCAGCACACAAAGCCAAAAATTTATAAATTGTCACCTGTGCAAAG, BIP-TATTGGTGGAGCTAAACTTAAAGCCACACTTTCTGTACAATCCCT T, Lb-GAATTTAGGTGAAACATTTGTCACG, and Lf- CTTAAAGAATGTCTGAACACTCTCC, and pE-2 sequences selected from: TABLE-US-00014 F3-CCGACGACGACTACTAGC, B3-GACTCACGTTAACAATATTGCA, FIP-ACTATTAACGTACCTGTCTCTTCCGGTGCCTTTGTAAGCACAAG, BIP-AGCGTACTTCTTTTTCTTGCTTTCGCAGTACGCACACAATCGA, Lb-CTTGCTAGTTACACTAGCCATCCT, and Lf- CGAATGAGTACATAAGTTCGTACTC.

30. A method of preparing an amplification solution for use in the method of claim 26, comprising: using primers comprising R1Aa2 sequences selected from: TABLE-US-00015 F3-TGCTTGTGAAATTGTCGGT, B3-GCCAGTTTCTTCTCTGGAT, FIP-TCAGCACACAAAGCCAAAAATTTATAAATTGTCACCTGTGCAAAG, BIP-TATTGGTGGAGCTAAACTTAAAGCCACACTTTCTGTACAATCCCT T, Lb-GAATTTAGGTGAAACATTTGTCACG, and Lf- CTTAAAGAATGTCTGAACACTCTCC, and pE-2 sequences selected from: TABLE-US-00016 F3-CCGACGACGACTACTAGC, B3-GACTCACGTTAACAATATTGCA, FIP-ACTATTAACGTACCTGTCTCTTCCGGTGCCTTTGTAAGCACAAG, BIP-AGCGTACTTCTTTTTCTTGCTTTCGCAGTACGCACACAATCGA, Lb-CTTGCTAGTTACACTAGCCATCCT, and Lf- CGAATGAGTACATAAGTTCGTACTC.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0030] FIG. 1 shows analytic sensitivity of the kit intended to detect Trypanosoma cruzi, the agent causing Chagas disease with purified genomic DNA.

[0031] FIG. 2 shows the limit of the Chagas kit in blood samples without purification.

[0032] FIG. 3 shows analytic specificity of the kit with DNA from the six DTUs of T. cruzi.

[0033] FIG. 4 shows analytic sensitivity of the kit for syphilis.

[0034] FIG. 5 shows a display of the result with visible light and UV of the detection of treponema with syphilis confirmed diagnosis.

[0035] FIG. 6 shows analytic sensitivity of the kit for detection of SARSCoV-2, with reading from direct display with the naked eye from genomic DNA (reference sample) isolated from the nasopharyngeal swab of a confirmed patient by the reference method (rt-PCR and clinical condition).

[0036] FIG. 7 shows analytic sensitivity of the kit for detection of SARS CoV-2 with a reference sample and phylogenetically-related virus genomic template samples, spatial concomitance virus and potential contaminating genomes of the sample.

[0037] FIG. 8 shows capability to detect SARS-CoV-2 using the kit on direct reference samples, of bucco-/naso-pharyngeal or saliva swab, inactivated by heat, and without carrying out any purification or additional extraction steps.

[0038] FIG. 9 shows a perspective view of hermetically sealed sample boxes.

DETAILED DESCRIPTION OF THE INVENTION

[0039] The present invention consists of an extremely easy-to-use molecular-based diagnostic kit for detection of specific nucleotide sequences such as DNA, DNA copy and RNA, useful for detecting infectious agents, transgenes, specific alleles and non-encoding sequences, the kit comprising the following components: [0040] a first calibrated dropper bottle with an anti-contamination system containing a solution of the isothermally-functioning polymerase enzyme, the 4 types of deoxynucleotides, i.e. dATP, dCTP, dGTP and dTTP, saline and buffer solutions, chaotropic agent betaine, and a non-ionic detergent. [0041] a second calibrated dropper bottle with an anti-contamination system containing at least a set of 4 or 6 necessary primers to multiply DNA, DNA copy or RNA fragments, the latter being, in a first step, undistinguishable within the reaction passed to DNA copy, the specific sequence to be detected, i.e. pathogenic agent, transgene, allele, etc.; [0042] as an alternative to the two dropper bottles mentioned above, a single calibrated dropper bottle may be provided, said bottle with an anti-contamination system, containing a solution with the 4 types of deoxynucleotides, i.e. dATP, dCTP, dGTP y dTTP, saline and buffer solutions, chaotropic agent betaine, a detergent, and the set corresponding to 4 or 6 primers, wherein the polymerase enzyme is lyophilized in the interior of the hermetically-sealed carrier where the amplification reaction is to be carried out; [0043] an alternative embodiment with a single calibrated dropper bottle containing a solution of the 4 types of deoxynucleotides, i.e. dATP, dCTP, dGTP and dTTP, saline and buffer solutions, chaotropic agent betaine, a detergent, the Bst enzyme and, in case of detection of RNA virus, the reverse transcriptase; wherein the primers and the indicating dye are dehydrated in the interior of the hermetically-sealed carrier where the amplification reaction is to be carried out; [0044] optional embodiment: in an optional embodiment of the kit, hermetically-sealed tubes or carriers may be included, in which the reagents with the sample are placed and the reaction is carried out; [0045] a third dropper bottle with developing solution; [0046] thin layer chromatography strips by lateral flow or simply reactive lateral flow dipsticks (LFD); [0047] for embodiments with color or fluorescence reading, LFDs are omitted; additionally, when the dying and/fluorescent compound is found in one of the reaction mixtures of the calibrated dropper bottles or else dehydrated in the reaction tube, the developing dropper bottle is also omitted; [0048] to verify correct kit performance, a set of positive and negative controls is provided, namely: [0049] positive control: consisting of a pattern sequence, that is an amplification template consisting of a nucleotide sequence equal to that intended to be detected, and [0050] negative control: consisting of the empty reaction carrier, such as a tube or filter paper in the tube, with no specific template; alternatively, the carrier is inoculated with a control genome not homologous to the sequence to be detected.

[0051] The calibrated dropper bottles that are used for the reagent mixtures must comply with the design standards such that there is no sterility loss during their use. Eventually, they may be replaced by common dropper bottles with calibrated drop provided a preservative is added to the reactive. Preservatives may be selected from the group consisting of commercially-available preservatives or others known in the prior art: benzyl alcohol, cetrimide, benzalkonium chloride, cetylpyridinium chloride, benzethonium chloride, benzoic acid and salts thereof, sorbic acid and salts thereof, parabens, phenoxyethanol, phenylethanol, disodium EDTA and others known in the prior art and mixtures thereof, the selection of which is made upon testing their performance in each particular case.

[0052] In this kit, one or two reagent mixtures are present, which are directly administered with a dropper bottle of sterile calibrated drops. This technology, being novel in kits of molecular biology or molecular diagnosis, allows for the addition of reagents in a simplified and effective manner.

[0053] In the present invention, particularly appropriate to detect pathogenic agents or else transgenic, allelic, non-encoding or own sequences in a sensitive, specific and simple manner, the biological sample is placed on a carrier, incubation takes place during 30 to 60 minutes at 62 to 64° C., and the result is revealed, by alternative means, depending on the sample type and case convenience, the entire procedure taking a time slightly longer than one hour. Among the reading options, those of color change and/or fluorescence, or else of the addition of a lateral flow dipstick (LFD) are found. The dipstick is a developing alternative when the presence of color of the unprocessed sample, or the carrier, could interfere with the color or fluorescence signal of the reaction.

[0054] The first use steps of the diagnostic kit reveal small variations depending on the selected carrier; “carriers” being those elements where the sample to be analyzed is placed.

[0055] In one embodiment of the invention, the carrier is a reaction tube made of classic plastic material, for example, polypropylene or the like, that is hermetically sealed.

[0056] A second carrier is a hermetically sealed reaction tray where the sample is placed, optionally with a saline solution, and the reagents; it comprises a lateral slot through which the developing system is introduced by the dipstick.

[0057] It is made of a material that allows for heating thereof for reaction incubation.

[0058] A third carrier is a filter paper (Guthrie type or the like). A portion of the paper with the sample is embedded and is introduced into the reaction tube or tray to continue with the diagnostic process.

[0059] In those cases in which the sample carrier is a hermetically-sealed reaction tube or tray, the sample, i.e. blood, saliva, etc. must be placed into said carrier, whether tube or tray. Optionally, depending on the nature and condition of the sample to be tested, for example, whole liquid blood, an amount of saline solution may be placed to dilute the sample, when said action could enhance reaction sensitivity.

[0060] In case the sample carrier is a filter paper (Guthrie type or the like), the filter paper or the like must become impregnated with the sample, i.e. blood, tear, saliva, etc. The impregnated portion of the filter paper is placed into the reaction tube or tray, optionally an amount of saline solution may be added to dilute the sample, when said action could enhance reaction sensitivity.

[0061] Whatever the selected carrier may be, to proceed with the amplification reaction of the present invention, at least one drop from the first dropper bottle is placed into the reaction tube or tray and, if appropriate, at least one drop from the second dropper bottle is introduced into the reaction tube or tray. It is hermetically sealed and mixed until homogenization of the solution ingredients. It is incubated with a heat source at 63-65° C. for 30-60 minutes; thereafter the heat source is removed.

[0062] In the embodiments of the invention including development by dipstick (LFD), once incubation is completed, a drop from the developing dropper bottle is added into the reaction tube or tray, and a dipstick (LFD) is introduced. In the case of a reaction tube, the dipstick is introduced through the tube mouth; in the case of a reaction tray, the dipstick is introduced through the lateral slot. The reaction mixture is allowed to progress by capillarity along the LFD for 2-5 minutes, the LFD is removed and the result is read, where 2 precipitation lines or bands is a reagent positive result; 1 precipitation line or band is a reagent negative result; no precipitation line or band is an invalid result.

[0063] In the case of a colorless sample, such as exudate, mucus, serum, etc., the developing system by dipsticks may be replaced by chromophore and/or fluorophore compound changing. To this end, the LFD system and its dropper bottle is substituted by the color reading system, which result may be detected with the naked eye and/or by UV irradiation fluorescence using a chromophore and/or fluorophore compound. Said compound may be found: in one of the calibrated dropper bottles, present during the amplification reaction; in an ‘ad hoc’ developing dropper bottle, where the developing solution is added at the end of the incubation; dispensed in dehydrated manner in the reaction carrier provided by the kit, on the base thereof or else on the lid, in which case it shall be mixed with the reaction product, by reversion, at the end of the incubation.

[0064] In cases where the material to be detected is of DNA or ribonucleic nature, a prior reverse transcription reaction independently of the kit may be carried out, or else the presentation of the kit that is adapted to said biological material may be used, because the reverse transcription followed by the amplification in a single operative step occurs.

Example 1

[0065] Diagnostic kit for detecting the presence of Trypanosoma cruzi, Chagas disease etiological agent, in biological samples.

[0066] Chagas disease was originally limited to certain rural areas of Latin America. With climate change and present migration currents, the infectious agent is presently found in traditionally non-endemic, rural and urban areas, throughout the world.

[0067] Chagas detection in newborns is usually made by techniques of display of parasite Trypanosoma cruzi in the blood, such as microhematocrit, microStrout, etc. Only in certain premises with adequate infrastructure, human resources and economic conditions, eventually, PCR or Real time PCR techniques are also carried out, as from pure DNA. Similar procedures are applied to detection in immunocompromised subjects and in suspected acute cases.

[0068] The present kit for detecting Chagas disease has been conformed to “Point of Care” conditions, i.e. with scarce laboratory resources, and under field conditions. The kit has been adapted to be applied using a blood sample obtained from the newborn heel and dispensed on a filter paper, or else from a patient's anticoagulated blood with guanidium chloride—EDTA or with EDTA only. The kit can also be used with pure DNA or from other biological samples, for example, patient's cerebrospinal fluid with reactivated Chagas disease. In this kit, the polymerase enzyme is Bst 2.0.

[0069] The Bst enzyme family is formed by DNA polymerase/helicase, using in this invention those without exonuclease activity such as Bst large fragment, Bst 2.0 and Bst 3.0, which features can be found in: FAQ: When should Bst DNA Polymerase be the enzyme of choice?, New England BioLabs Inc., 240 County Road, Ipswich, Mass. 01938-2732, USA (https://www.neb.com/faqs/0001/01/01/when-should-bst-dna-polymerase-be-the-enzyme-of-choice), and Bst DNA Polymerase—Heat-resistant strand displacement DNA polymerase, Nippon Gene CO., Ltd., 2-7-18, Toiya-machi, Toyama 930-0834, Japan (http://nippongene.com/english/product/modifying-enzymes/bst-dna20 polymerase.html).

[0070] In this kit for detecting Trypanosoma cruzi, the set of primers consists of 6 oligonucleotide sequences:

[0071] 1—Forward Inner Primer (FIP): genetically-engineered sequence not found in nature.

[0072] 2—Forward Outer Primer (F3): genetically-engineered sequence coupled with an immunoreactive protein, for example, biotin or fluorescein, that it is not the protein coupled in the B3.

[0073] 3—Forward Loop Primer (FLP): sequence present in the loop formed in the 5′ region of the amplicon. Under unfavorable reaction conditions—for example, due to excess of certain serum proteins in the sample—the presence of this primer enhances sensitivity, its presence being indistinct under other conditions.

[0074] 4—Backward Inner Primer (BIP): genetically-engineered sequence not found in nature.

[0075] 5—Backward Outer Primer (B3): genetically-engineered sequence coupled with an immunoreactive protein, for example, biotin or fluorescein, that it is not the protein coupled in the F3.

[0076] 15—Backward Loop Primer (BLP): sequence present in the loop formed in the 3′ region of the amplicon. Under unfavorable reaction conditions—for example, due to excess of certain serum proteins in the sample—the presence of this primer enhances sensitivity, its presence being indistinct under other conditions.

[0077] In this kit, the developing system is that of LFD type dipsticks, of the type of those described in U.S. Pat. No. 6,656,744, with 2 areas of molecular interaction, each of which being capable of exclusively interacting with one or other immunoreactive protein coupled to primers F3 and B3.

[0078] In this kit, the developing solution consists of Tris buffered saline, which provides molecules coupled to colloidal gold solution, supplementary to the immunoreactive proteins coupled to primers, and facilitates the reaction progress over the developing stick by capillarity and which ionic strength and pH facilitate the interaction of immunoreactive proteins coupled to both primers with the corresponding molecules supplementary to the stick and the solution.

[0079] Analytical tests have shown sensitivity of 0.1 femtograms of DNA, equivalent to 0.001 parasites, either in solution or dispensed on filter paper (Guthrie type or the like), as well as the detection of one (1) parasite in a blood sample artificially inoculated and dispensed on filter paper and directly used in the reaction. The kit showed excellent performance in specificity, without evidencing crossed reaction with genetic material of other phylogenetically related species, such as Leishmania spp., Trypanosoma brucei, Trypanosoma rangeli, or the like, that are contaminants to the sample, such as human DNA, yeast DNA.

[0080] According to FIG. 1, analytical sensitivity of this kit with purified genomic DNA may be observed. The detection limit of the reaction with the kit was observed using serial 10-fold dilutions from 10 nanograms to 0.01 femtograms of purified genomic DNA as of T. cruzi, CL Brener strain, DTUVI (DTU “Discrete Typing Unit”) VI. Similar results are obtained with strains of all DTUs:

[0081] a) Development through agarose gel electrophoresis 1.5% w/v, TAE 1 X, Sybr Safe 1X (analytical method).

[0082] b) Development with the POC method using the LFD sticks of the kit.

[0083] The upper arrow defines the control line or band, present in all reactions, whether positive or negative, and the lower arrow corresponds to positive amplification band, where, Neg: control of reagents without genomic DNA, which must always be negative.

[0084] In FIG. 2, the detection limit of Trypanosoma cruzi, the agent causing Chagas disease tested in blood samples without purification, dispensed on paper (Guthrie type or the like), inoculated with a controlled number of parasites, is shown.

[0085] Upon applying the kit directly in non-purified human blood samples artificially inoculated with a controlled number of whole parasites, among 1 and 1,000 parasites, dispensed on paper (Guthrie type or similar), optimal analytical sensitivity is observed, that is the detection of only one parasite per reaction.

[0086] a) samples inoculated with T. cruzi epimastigotes, CL Brener strain.

[0087] b) samples inoculated with CL Brener tripomastigotes.

[0088] Similar results are obtained with all DTUs: where, P: number of inoculated parasites; Neg: control of reagents without template, which must always be negative.

[0089] In FIG. 3, tested analytical specificity of the kit with DNA of the six DTUs of T. cruzi, related species and contaminating species, may be observed.

[0090] Tests of the kit with DNA of the six DTU of T. cruzi; human cells (HELA), since it is a material present in the samples; yeast Saccharomyces cerevisiae (S. cere), a frequent contaminant; and of species related to the parasite: Crithidia fasciculata (C. fasc), T. brucei (T. Br); Leishmania mexicana (L. Mex), Phytomonas spp (Phyto), T. rangeli SC-58 strain (T. Rang Sc) and T. rangeli Choachi strain (T. Rang Ch)..sub.i, were informed; where Neg: control of reagents without genomic DNA, which must always be negative; Pos: control of amplification using 1 pg of genomic DNA, which must always be positive.

[0091] These results confirm specificity of the kit to recognize all Trypanosoma cruzi genetic variants and that no crossed reaction occurs with other species, including those very similar due to their phylogenetic proximity.

Example 2

[0092] Diagnostic kit for detecting the presence of Trypanosoma pallidum pallidum, etiological agent of Syphilis, in biological samples.

[0093] Syphilis is a sexually transmitted bacterial infection (STI) caused by Treponema pallidum pallidum. Despite having safe prophylactic measures, such as, for example, the use of condoms, and efficient and economic therapies, for example, using penicillin, this disease constitutes a global problem, with at least 12 million new cases of infection each year. Either in cases of syphilis in adults as in congenital syphilis, where late diagnosis and treatment occur, bacterial dissemination in the whole body is seen, which may result in neurologic and cardiovascular disorders.

[0094] Syphilis diagnosis is currently made by:

[0095] i—Microscope observation of T. pallidum;

[0096] ii—“Treponomic”-type serological methods, with which antibodies against specific antigens of T. pallidum are detected; and

[0097] iii—Non-treponomic type serological methods, with which antibodies against reaginic antigens, existing on damaged tissue, either by T. pallidum or for other reasons are detected, the positivity of which is not confirmed.

[0098] These methods for detecting syphilis, in general terms, are not effective in newborns, for which reason most alive, infected newborns (˜80%)—that are asymptomatic at the time of birth—will not be detected early.

[0099] The methods of molecular detection of syphilis as well as Chagas disease developed up to the present time do not adapt to the general conditions found in the Public Health institutions of Argentina, for which reason they remain restricted only to certain medical care centers, and leave a vacancy for new specific, sensitive methods applicable to all sanitary conditions.

[0100] The kit of the present invention for detecting syphilis is adapted to Point of Care conditions. In this kit, as described in Example 1, polymerase enzyme is also Bst 2.0, and the set of primers is formed by 6 specific oligonucleotides of the Treponema pallidum pallidum sequence to be detected (FIP; F3; FL; BIP; B3 and BL).

[0101] In this kit for detecting treponoma in a colorless sample of, for example, exudate, mucus, serum, etc., the result reading system is made by color change which may be detected with the naked eye and/or UV irradiation fluorescence, using the intercalating compound “Sybr Green”. To ensure stability of the reading system in this disclosure, said compound has been dispensed on the lid of the reaction tube provided in the kit, under dehydrated condition, and it is mixed with the reaction product at the end of incubation at 63-65° C.

[0102] Alternatively, for detection of the treponema in samples with opacity or their own color, or else dispensed on a filter paper, the developing system is that of LFD dipsticks as the kit of the Example 1.

[0103] In FIG. 4, analytical sensitivity of the kit for syphilis in samples of serum artificially inoculated can be observed, using different methods displaying the result.

[0104] The reaction with the kit was made to detect treponema in human serum samples 1/100 diluted, artificially inoculated with a controlled number of copies of treponema template of interest (among 1 and 100 copies) dispensed in reaction tubes. Optimal analytical sensitivity is seen, that is the detection of only one bacterium, in the different reading methods:

[0105] a) analytical method, through agarose gel electrophoresis;

[0106] b) color change; and

[0107] c) reading method through LFD.

[0108] In this way, lane 1: negative control corresponding to 1 picogram of E. coli DNA, which represents approximately 200 genome copies; lane 2: serum dilution with 100 copies of T. pallidum nucleotide sequence used as template; lane 3: serum dilution with 10 template copies; and lane 4: serum dilution with 1 template copy in the reaction.

[0109] In FIG. 5, the results obtained through the kit for detecting treponema in control serum samples and in a patient with confirmed diagnosis of syphilis by means of visible light and UV display, are seen.

[0110] In this FIG. 5, 3 negative reactions are observed, as follows: 1, 2 and 3: carried out with non-infected serum, artificially inoculated with 1 picogram of E. coli DNA, approximately 200 genome copies, and 3 positive reactions, namely: 4, 5 and 6: triplicates of a reaction made with a 1/1000 dilution of a serum sample from a patient with confirmed infection, seen with the naked eye or else by UV light irradiation.

[0111] Under controlled conditions, the kit provides, with both readings, an analytical detection limit of a copy per reaction.

[0112] To assess the number of copies present in the serum sample from the patient, complementary molecular assays by means of Real Time PCR with serial dilutions of the sample and the cloned sequence, used as positive control, were made.

[0113] These results show that the kit provides specific amplification for T. palladium pallidum, since no false positives are obtained in negative or DNA inoculated controls of other bacteria, of human or yeast origin. The detection limit obtained, of only one copy of DNA template per reaction, is similar to the different reading methods, the method of color change being very appropriate for POC conditions. In the literature, the reading system with UV is found to be more sensitive than that with visible light; however, when applying this kit under controlled conditions, the above-mentioned difference is not seen, probably given to the high efficiency of amplification for which, having only one initial copy, the amplification product is sufficiently high to be detected by both reading forms with substantially the same sensitivity.

Example 3

[0114] Diagnostic kit for detecting the presence of SARS-CoV-2, COVID-19 agent, in biological samples.

[0115] This kit detects the infection caused by SARS-CoV-2, etiological agent of atypical pneumonia (COVID-2019, “Corona Virus Disease 2019”), by reverse transcription followed by molecular amplification of specific regions of the SARS-CoV-2 genome, in only one step, from isolated RNA or directly from a clinical sample, without any extraction/purification steps, from infected patients, and inactivated at 65° C.—30 minutes as suggested by the American Type Culture Collection (ATCC) 10801 University Boulevard, Manassas, Va. 20110 USA (https://www.atcc.org/en/Global/Products/VR-1986HK.aspx#characteristics).

[0116] This diagnosis is presently made by:

[0117] i) Serological methods: these methods may be conventional, such as those conducted at a biochemical laboratory with commercial or homemade kits, or else kits of rapid configuration. These tests, apart from being rapid, are relatively inexpensive and do not need complexity in infrastructure or equipment. However, they may lead to false negative cases, because there is a period of time between the infection and the appearance of specific antibodies.

[0118] ii) Molecular methods, by end point PCR and Real Time PCR: These methods, as discussed above, require certain degree of infrastructure, equipment and skilled human resources. The process of taking the sample, isolating the viral RNA, carrying out the amplification and analyzing/informing the result takes, in the best optimized cases, some 4-5 hours. To this, in many cases, the time of sample transportation from primary medical centers, where the sample collection takes place, to sites qualified to carry out the diagnosis by Real Time PCR, must be added. In the case of Argentina, delays of 6-7 days have been reported, with the resulting negative impact on the patient's life and their family of staying preventively isolated until having the result.

[0119] Recently, numerous kits of serological and molecular basis have appeared all over the world; among the latter, those 3 LAMP-based kits appear, with different configuration.

[0120] Ben Assa et al. (“SARS-CoV-2 On-the-Spot Virus Detection Directly From Patients”, Elect Jour Art, medRxiv, Cold Spring Harbor Laboratory Press, 10.1101/2020.04.22.20072389 (2020)) discloses an isothermal molecular method similar to that of the present invention. Although it is estimated that it can be used directly with the RNA sample without purification, matching values obtained in comparison with the RT-PCR method (standard method for these determinations) have a very high percentage of false negatives of more than 15% in all cases, even with an improved protocol. This may be because this kit has a very high detection limit compared to RT-PCR. When comparing this method with the one provided with the kit described in the present invention, it may be stated that the unexpected result obtained as to the match obtained with an RT-PCR used as a reference method by ‘ANLIS (National Bureau of Laboratories and Health Institutions) Mabrán’ of the Argentine Republic, may be concluded.

[0121] A molecular-based diagnostic kit based on isothermal nucleic amplification for COVID-19 has been approved and is already being marketed by Abbott Laboratories. In this case, the virus gene is only amplified, which implies that the negative results may only be reported as ‘presumptive’ and another kit is required to confirm them. Moreover, the detection limit is of 312.5 copies, that is 125 copies/mL in 2.5 mL of elution buffer. This kit, contrary to the kit of the present invention, requires equipment provided by Abbott. The kit of the present invention does not require any special equipment or higher technology, but only a thermal block.

[0122] On the other hand, document US 2020/0048722 A by Nyan, D. discloses multiple diagnosis methodology by isothermal nucleic amplification that detects pathogen presence by fluorometry. The present invention does not require either a fluorometer or any other type of equipment since detection is visual based on the color change with the naked eye.

[0123] In summary, these commercially-available kits either require technology that is not easily available or is sophisticated such as cyclers, fluorometers, etc., or else have a very lower sensitivity compared to the standard molecular methods of the RT-PCR type.

[0124] Thus, it is useful to have a rapid, sensitive and specific kit that does not require high technology equipment to perform disease diagnosis even in health centers with a reduced number of equipment or in the field. The present invention appears to overcome this particularly required need in the case of pandemics where instruments and supplies are scarce, and wherein a “Point of Care” diagnostic reagent, with an adequate sensitivity to allow for taking of decisions of immediate isolation or relocation of patients to avoid contagions and propagation of diseases, is required. With the kit of the present invention, SARS-CoV-2 is detected by means of a reverse transcription reaction to obtain viral DNAc followed by molecular amplification of only one operative step, at constant temperature of 63-65° C. Detection is multiple because 4 sets of primers that recognize and amplify 4 specific regions of the viral genome are used, ensuring sensitivity even in the light of a mutation that may, potentially and unlikely, affect the hybridization of some primers. For simplified reading, hydroxynaphthol blue (HNB) is used, an indicating dye that changes from violet to blue when amplification reaction is positive.

[0125] Said change is due to the change of Mg2+ free in solution as dNTPs decrease and the pyrophosphate product of the amplification increases.

[0126] In this kit, the HNB dye together with primers are dehydrated on the bottom of the reaction tube provided by the kit. These components are suspended with reaction mixture and the template, and then incubation at 63-65° C. takes place.

[0127] Analytical tests show sensitivity of 3.12 copies of SARS-CoV-2 viral genome from purified genomic RNA (reference sample).

[0128] In FIG. 6, analytical specificity of the kit for detection of SARS-CoV 2 according to the present invention can be observed by direct reading with the naked eye.

[0129] Successive dilutions were made from a reference sample of RNA isolated from naso-/bucco-pharyngeal swab. Tube 1: negative control, without template; tube 2: 40,000 copies; tube 3: 4,000 copies; tube 4: 400 copies; tube 5: 200 copies; tube 6: 100 copies; tube 7: 50 copies; tube 8: 25 copies; tube 9: 12.5 copies; tube 10: 6.25 copies; tube 11: 3.125 copies; tube 12: 1.56 copies of genome.

[0130] The kit discloses suitable specificity because no crossed reaction is seen using as a potential template the genetic material from other phylogenetically related species, such as, for example, canine coronavirus of spatial concomitance, such as H1N1, dengue, zika, chikungunya; neither with potentially contaminating genomes of the sample, such as bacteria, yeast and human's, using in all cases a mass 1,000 times greater than that used for SARS-CoV-2.

[0131] In FIG. 7, analytical specificity of the kit for detection of SARS-CoV 2 may be observed, challenged with genome samples from related species and contaminating species.

[0132] In this FIG. 7, duplicates of the reaction with different templates are shown: tubes 1-2: SARS-CoV-2; tubes 3-4: canine coronavirus; tubes 5-6: Influenza (H1N1); tubes 7-8: Dengue, mixture of the 4 serotypes; tubes 9-10: Zika; tubes 11-12: Chikungunya; tubes 13-14: bacterial template of E. coli; tubes 15-16 yeasts (Saccharomyces cerevisiae); tubes 17-18: yeasts (Saccharomyces pombe); and tubes 19-20: human cells (HELA).

[0133] Trials of the test were made using clinical bucco/naso-pharyngeal samples and saliva swab as template, inactivated at 65° C.—30 minutes as per indication of ATCC (American Type Culture Collection), with no extraction or purification steps. The kit shows amplification capability, either for swab sample as for saliva samples, for which reason it may be inferred that in sputum samples a positive result may likewise be obtained (assay not carried out). Inactivations were also conducted at 95° C.—5 minutes as indicated for Ebola in the General Procedures for the Inactivation of Potentially Infectious Samples with Ebola virus and other Highly Pathogenic Viral Agents, 2014-cha-procedimientos-inactivacion-ebola (https://www.paho.org/hq/dmdocuments/2014/2014-5 cha-procedimientos-inactivacionebola.pdf) attaining the same inactivation result.

[0134] In FIG. 8, the reaction result with the kit for detection of SARS-CoV 2 may be observed, applying direct clinical samples, without purification inactivated by heat.

[0135] A group of swab samples and of saliva of patients which were confirmed positive and negative, wherein the samples of these latter were used as a negative control, were inactivated by heat (65° C.—30 minutes); and were used as template for direct reaction of the kit for COVID-19. Tube 1: swab sample from negative patient; tube 2: swab sample from positive patient; tube 3: saliva sample from negative patient, 1/10 dilution in saline solution; tube 4: saliva sample from positive patient, 1/10 dilution in saline solution; tube 5: negative control, without template; and tube 6: positive control based on RNA of reference SARS-CoV-2.

Example 4

[0136] Determination of the detection limit of the kit for detecting SARS CoV 2.

[0137] To determine the detection limit, each operator (two in total) made repetitions of the reaction of the kit according to the present invention for COVID-19 with different amounts of purified RNA corresponding to the reference sample for SARS-CoV-2. In parallel, repetitions of a negative reference sample were made.

[0138] The results summarized in the following table were obtained:

TABLE-US-00001 Positive reference sample Negative (amount of copies of genome inoculated as template) reference 100 50 25 12.5 6.25 3.125 sample Reactions Copies copies copies copies copies Copies — Positive 10 10 10 10 8 5 0 Negative 0 0 0 0 2 5 10 % 100 100 100 100 80 50 100

[0139] It is concluded that the detection limit of the kit is 12.5 copies of SARS-CoV-2 RNA.

Example 5

[0140] Comparison of the kit for detecting SARS-CoV-2 of the present invention versus RT-PCR kits with samples coming from the national reference center of the Argentine Republic “ANLIS Mabrán”.

[0141] Parameter Definition

TABLE-US-00002 Reference technique RT-PCR Positive samples Negative samples Kit of the invention VP FP Positive Kit of the invention FN vn Negative

[0142] VP: True Positive; VN: True Negative; FP: False Positive; FN; False Negative.

[0143] Based on this picture, the following parameters of the kit are defined:

[0144] Sensitivity (%); VP/(VP+FN)×100

[0145] Specificity (%): VN/(VN+FP)×100

[0146] Accuracy (%): (VN+VP)/total×100

[0147] Study of sampling under clinical and trial conditions with the kit of the invention COVID-19 under controlled conditions.

[0148] 150 clinical reference samples were received, consisting of purified RNA from patients diagnosed by the RT-PCR of the “gold standard” method of COVID-19 emergency according to the WHO, 100 coming from positive patients and 50 from negative patients. Likewise to the RT-PCR, 5 μl of purified RNA by a commercial kit for the extraction of nucleic acids by microcolumn (microcolumns identified as RNA spin Qiagen, or similar) as template for the test of the kit of the present invention COVID-19, were used.

[0149] Results obtained in both methods are compared on a contingency table of 2×2, defining the performance parameter, sensitivity and specificity of the kit of the present invention COVID-19.

[0150] Results

[0151] Results obtained in the 150 clinical samples tested by the kit of the present invention for COVID-19, taking the RT-PCR as a Gold Standard method of COVID-19 emergency, show a 100% matching, for which they evidence 100% sensitivity and 100% specificity (FIGS. 5A and B), as shown in the following table:

[0152] Parameter Definition

TABLE-US-00003 Reference technique RT-PCR Positive samples Negative samples total Kit of the invention VP FP Positive Kit of the invention FN VN Negative

[0153] VP: True Positive; VN: True Negative; FP: False Positive; FN; False Negative.

[0154] Based on this picture, the following parameters of the kit are defined:

[0155] Sensitivity (%); VP/(VP+FN)×100

[0156] Specificity (%): VN/(VN+FP)×100

[0157] Accuracy (%): (VN+VP)/total×100

[0158] 100% matching as to negative samples was found. As to positive samples, there were 6 that showed non-matching, being positive for RT-PCR and negative for the kit of the present invention. These samples were repeated with the kit recommended by CDC ‘Centers for Disease Control and Prevention’, USA (“CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel”, CDC-006-00019, Revision 04, CDC/DDID/NCIRD/Division of Viral Diseases, 12/6/2020), the result matching with that of the present invention. Therefore, defective conservation of samples that caused degradation during their storage for more than 1 week, is evident. Taking this into account, the following table was made:

[0159] Contingency table as per results forwarded by the Referring ‘ANLIS-Malbrán’ and verified with CDC 2019-nCoV Real Time RT-PCR Diagnostic Panel

TABLE-US-00004 Reference technique RT-PCR Positive samples Negative samples total Kit of the invention 94 0 94 Positive Kit of the invention 0 56 56 Negative Totals 94 56 150

[0160] Under these conditions, the following parameters are obtained:

[0161] Sensitivity: 100%

[0162] Specificity: 100

[0163] Accuracy: 100%

Example 6

[0164] Inter-laboratory trial with the kit for detecting SARS CoV-2 of the invention with those obtained with RT PCR kits of different COVID-19 diagnostic centers of the Argentine Republic.

[0165] The following COVID-19 diagnostic centers have taken part in this inter-laboratory trial, which used RT PCR kits:

TABLE-US-00005 Diagnostic center Location Rossi Hospital La Plata, Province of Buenos Aires, AR San Juan de Dios Hospital La Plata, Province of Buenos Aires, AR ANLIS Malbrán Autonomous city of Buenos Aires, AR San Fernando Hospital San Fernando, Province of Buenos Aires, AR Muñiz Hospital Autonomous City of Buenos Aires, AR Abete Hospital Malvinas Argentinas, Province of Buenos Aires, AR Public Health Laboratory, La Plata, Province of Buenos Aires, AR School of Exact Sciences, National University of La Plata

[0166] The total results obtained in the inter-laboratory trial are stated in the following contingency table:

TABLE-US-00006 Reference technique RT-PCR Positive samples Negative samples total Kit of the invention 201 6 207 Positive Kit of the invention 7 227 234 Negative Total 208 233 441

[0167] Sensitivity: 96.6%

[0168] Specificity: 97.4

[0169] Accuracy: 97.0%

[0170] This inter-laboratory trial shows an extremely favorable matching and over 95% based on the three more relevant parameters of diagnostic kits. This is particularly remarkable if we take into account that in this trial: [0171] Several Argentine diagnostic centers took part. [0172] RT-PCR methods of different commercial trademarks, approved by the competent sanitary authority, i.e. National Administration of Drugs, Food and Medical Technology (ANMAT) of Argentina, such as: GeneFinder RealAmp SARS-CoV-2; RT-PCR Light Mix® Modular SARS-CoV-2; or the like, were used. [0173] Samples, in general, could not be analyzed by the kit of the invention simultaneously with RT-PCR, for which reason some or all of the mismatches could be explained by some alteration of the integrity of the sample during storage. Besides, there exist other random variables, such as: inhomogeneity of the sample as to viral load, human mistake when making determination, etc.

[0174] Original Primer Sequences

[0175] https://www.epo.org/applying/online-service/online-filing/auxiliary/bissap.html

TABLE-US-00007 KIT SEQUENCES 1 - kit for SAT gene F3- ACAGAGAGTGCCTCTGA (SEQ ID NO: 1) Chagas sequences B3- GTCAATATCTGTTTGCG (SEQ ID NO: 2) FIP- CACTCGGCTGATCGTTTTCGACCCCCATCATTCATAATTGGA (SEQ ID NO: 3) BIP- GGCAAGAGCTCGCGAAATTCCACACACTGGACACCAAA (SEQ ID NO: 4) Lb- TCCAAGCAGCGGATAATTCA (SEQ ID NO: 5) Lf- TGCATCACATGTTGTGGTCTA (SEQ ID NO: 6) 2 - kit for PolA gene F3- ATTGGTCCTAAGACGGCT (SEQ ID NO: 7) Syphilis sequence B3- GCGGAATACAACAGGAATC (SEQ ID NO: 8) FIP- CAGCGCTTCTTTTAAGGAATAGGTAGCACATCTTCTCCACTGT (SEQ ID NO: 9) BIP- CGCACGAAGATAGTGTGTGGACATGGTACATCGTCACG (SEQ ID NO: 10) Lb- GAAGAAAGATGCATTTTTTTCTCGTTC (SEQ ID NO: 11) Lf- CGATAAATACCATCAAGTGTGCCAAA (SEQ ID NO: 12) 3 - kit for R1Aa2 F3- TGCTTGTGAAATTGTCGGT (SEQ ID NO:  13) COVID-19 sequences B3- GCCAGTTTCTTCTCTGGAT (SEQ ID NO: 14) FIP- TCAGCACACAAAGCCAAAAATTTATAAATTGTCACCTGTGCAAAG (SEQ ID NO: 15) BIP- TATTGGTGGAGCTAAACTTAAAGCCACACTTTCTGTACAATCCCTT (SEQ ID NO: 16) Lb- GAATTTAGGTGAAACATTTGTCACG (SEQ ID NO: 17) Lf- CTTAAAGAATGTCTGAAGAGTCTCC (SEQ ID NO: 18) F3- CCGACGACGACTACTAGC (SEQ ID NO: 19) pE-2 B3- GACTCACGTTAACAATATTGCA (SEQ ID NO: 20) sequence FIP- ACTATTAACGTACCTGTCTCTTCCGGTGCCTTTGTAAGCACAAG (SEQ ID NO: 21) BIP- AGCGTACTTCTTTTTCTTGCTTTCGCAGTACGCACACAATCGA (SEQ ID NO: 22) Lb- CTTGCTAGTTACACTAGCCATCCT (SEQ ID NO: 23) Lf- CGAATGAGTACATAAGTTCGTACTC (SEQ ID NO: 24)